结直肠癌
医学
免疫疗法
免疫系统
肿瘤微环境
癌症
转移
癌症研究
免疫学
肿瘤科
内科学
作者
Runzhi Deng,X. W. Zheng,Zhonglei Lu,Yuan Ming,Qing-gang Meng,Tao Wu,Yu Tian
标识
DOI:10.4251/wjgo.v16.i11.4354
摘要
The relevant mechanism of tumor-associated macrophages (TAMs) in the treatment of colorectal cancer patients with immune checkpoint inhibitors (ICIs) is discussed, and the application prospects of TAMs in reversing the treatment tolerance of ICIs are discussed to provide a reference for related studies. As a class of drugs widely used in clinical tumor immunotherapy, ICIs can act on regulatory molecules on cells that play an inhibitory role - immune checkpoints - and kill tumors in the form of an immune response by activating a variety of immune cells in the immune system. The sensitivity of patients with different types of colorectal cancer to ICI treatment varies greatly. The phenotype and function of TAMs in the colorectal cancer microenvironment are closely related to the efficacy of ICIs. ICIs can regulate the phenotypic function of TAMs, and TAMs can also affect the tolerance of colorectal cancer to ICI therapy. TAMs play an important role in ICI resistance, and making full use of this target as a therapeutic strategy is expected to improve the immunotherapy efficacy and prognosis of patients with colorectal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI